The Effectiveness of Intravitreal Ranibizumab in Patients with Diabetic Macular Edema Who Have Failed to…

Cohort studyOphthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift fur Augenheilkunde· 2016

The Effectiveness of Intravitreal Ranibizumab in Patients with Diabetic Macular Edema Who Have Failed to Respond to Intravitreal Bevacizumab.

Rita Ehrlich, Idit Dan, Iris Deitch … Karin Mimouni

Read paper

EndocrinologyCohort studyTreatmentQ2IF 2.3

After switching to ranibizumab, 57% of diabetic macular edema eyes had improved vision.

The Effectiveness of Intravitreal Ranibizumab in Patients with Diabetic Macular Edema Who Have Failed to Respond to Intravitreal Bevacizumab.

Rita Ehrlich … Karin Mimouni

Ophthalmologica · 2016 · Q2 in Ophthalmology

Purpose

To investigate the response to intravitreal ranibizumab after failure of intravitreal bevacizumab in patients with diabetic macular edema (diabetic macular edema).

Methods

Demographics, visual acuity (visual acuity), central macular thickness (central macular thickness), and HbA1C were retrospectively collected from diabetic macular edema patients treated with second-line intravitreal ranibizumab at a tertiary hospital in 2012-2013 and followed for at least 3 months.

n = 26 eyes

57%

Results

57%

eyes could see better after three ranibizumab injections

n = 26 eyes

More results

The mean number of intravitreal bevacizumab injections was 7.3 ± 2.8, and of intravitreal ranibizumab injections 5.11 ± 2.4.

The change in visual acuity was statistically significant (p = 0.044) in those eyes where the pretreatment acuity for the second-line therapy was <20/40 (logMAR 0.3).

More results

Central macular thickness decreased from 435.95 ± 83.28 to 373.69 ± 44.39 µm (p = 0.01).

The number of ranibizumab injections was significantly correlated with the change in central macular thickness (p = 0.037).

“

Conclusion

Intravitreal treatment with ranibizumab can be efficacious in eyes with diabetic macular edema that have failed to respond to bevacizumab.

The Effectiveness of Intravitreal Ranibizumab in Patients with Diabetic Macular Edema Who Have Failed to Respond to Intravitreal Bevacizumab.

The Effectiveness of Intravitreal Ranibizumab in Patients with Diabetic Macular Edema Who Have Failed to Respond to Intravitreal Bevacizumab.

Related papers